FI971026A - Kinoxalindion-NMDA-reseptorantagonister - Google Patents

Kinoxalindion-NMDA-reseptorantagonister Download PDF

Info

Publication number
FI971026A
FI971026A FI971026A FI971026A FI971026A FI 971026 A FI971026 A FI 971026A FI 971026 A FI971026 A FI 971026A FI 971026 A FI971026 A FI 971026A FI 971026 A FI971026 A FI 971026A
Authority
FI
Finland
Prior art keywords
pct
alkyl
group
date mar
ch2ch3
Prior art date
Application number
FI971026A
Other languages
English (en)
Finnish (fi)
Other versions
FI113471B (sv
FI971026A0 (sv
Inventor
Charles Eric Mowbray
Alan Stobie
David John Bull
Christopher Lee Carr
Michael Jonnathan Fray
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI971026A publication Critical patent/FI971026A/sv
Publication of FI971026A0 publication Critical patent/FI971026A0/sv
Application granted granted Critical
Publication of FI113471B publication Critical patent/FI113471B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
FI971026A 1994-09-13 1997-03-12 Kinoxalindion-NMDA-reseptorantagonister FI113471B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9418443 1994-09-13
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents
PCT/EP1995/003483 WO1996008485A1 (en) 1994-09-13 1995-09-01 Quinoxalinedione nmda receptor antagonists
EP9503483 1995-09-01

Publications (3)

Publication Number Publication Date
FI971026A true FI971026A (sv) 1997-03-12
FI971026A0 FI971026A0 (sv) 1997-03-12
FI113471B FI113471B (sv) 2004-04-30

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971026A FI113471B (sv) 1994-09-13 1997-03-12 Kinoxalindion-NMDA-reseptorantagonister

Country Status (14)

Country Link
US (1) US5783572A (sv)
EP (1) EP0781279B1 (sv)
JP (1) JP2898097B2 (sv)
AT (1) ATE202099T1 (sv)
CA (1) CA2199845C (sv)
DE (1) DE69521323T2 (sv)
DK (1) DK0781279T3 (sv)
ES (1) ES2158126T3 (sv)
FI (1) FI113471B (sv)
GB (1) GB9418443D0 (sv)
GR (1) GR3036270T3 (sv)
MX (1) MX9701894A (sv)
PT (1) PT781279E (sv)
WO (1) WO1996008485A1 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
ZA9710553B (en) * 1996-11-25 1998-06-10 Warner Lambert Co Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists.
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー ユニバーシティ pHに依存するNMDAレセプターアンタゴニスト
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CA2590997A1 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CN103497114A (zh) 2007-06-29 2014-01-08 埃莫里大学 用于神经保护的nmda受体拮抗剂
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
KR20130101576A (ko) * 2010-12-13 2013-09-13 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung

Also Published As

Publication number Publication date
DK0781279T3 (da) 2001-09-03
PT781279E (pt) 2001-09-28
GB9418443D0 (en) 1994-11-02
CA2199845A1 (en) 1996-03-21
CA2199845C (en) 2000-08-01
JP2898097B2 (ja) 1999-05-31
FI113471B (sv) 2004-04-30
DE69521323D1 (de) 2001-07-19
US5783572A (en) 1998-07-21
WO1996008485A1 (en) 1996-03-21
MX9701894A (es) 1997-06-28
JPH09511523A (ja) 1997-11-18
FI971026A0 (sv) 1997-03-12
EP0781279B1 (en) 2001-06-13
DE69521323T2 (de) 2001-09-20
GR3036270T3 (en) 2001-10-31
EP0781279A1 (en) 1997-07-02
ES2158126T3 (es) 2001-09-01
ATE202099T1 (de) 2001-06-15

Similar Documents

Publication Publication Date Title
FI971026A (sv) Kinoxalindion-NMDA-reseptorantagonister
FI962753A (sv) Förfarande för framställning av en som läkemedel användbar cyklisk aminkomposition eller ett farmaceutiskt salt därav
GB9126260D0 (en) Therapeutic agents
ZA928682B (en) Acyclic ethylenediamine derivatives
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
NZ508910A (en) Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
DE69402981D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
NZ333513A (en) 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
SE9703377D0 (sv) New compounds
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
DE69430068D1 (de) Benzodiazepinderivate
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
MA26724A1 (fr) 1,2,3,4-tetrahydro-1-naphtalenamines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: PFEIZER IRELAND PHARMACEUTICALS

Free format text: PFEIZER IRELAND PHARMACEUTICALS